


Georgia Center for Oncology Research and Education, Inc.

Independent Auditor's Report and
Audited Financial Statements

For the Year Ended June 30, 2022



Georgia Center for Oncology Research and Education, Inc.

Table of Contents

	<u>Page</u>
Independent Auditor's Report	2
Financial Statements	
• Statement of Financial Position for the Year Ended June 30, 2022	5
• Statement of Activities for the Year Ended June 30, 2022	6
• Statement of Functional Expenses for the Year Ended June 30, 2022	7
• Statement of Cash Flows for the Year Ended June 30, 2022	8
Notes to Financial Statements	9
Report on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance in Accordance with The Uniform Guidance	16
Schedule of Findings and Questioned Costs	19
Schedule of Expenditures of Federal and State Awards	20
Summary of Schedule of Prior Year Findings and Questioned Costs	21

Independent Auditor's Report

To Management and the Board of Directors
Georgia Center for Oncology Research and Education, Inc.
Atlanta, Georgia

Opinion

We have audited the accompanying financial statements of Georgia Center for Oncology Research and Education, Inc. (a not-for-profit organization), which comprise the statement of financial position as of June 30, 2022, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements present fairly, in all material respects, the financial position of Georgia Center for Oncology Research and Education, Inc. as of June 30, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (U.S. GAAS) and the standards applicable to financial audits contained in Government Auditing Standards (GAS), issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinions.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with U.S. GAAP, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with U.S. GAAS and GAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with U.S. GAAP and GAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards, as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with U.S. GAAS. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with GAS, we have also issued our report dated February 27, 2023 on our consideration of the Organization's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Organization's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with GAS in considering the Organization's internal control over financial reporting and compliance.



K. Glenn Aldridge, PC
(d/b/a Aldridge & Associates)
February 27, 2023

Georgia Center for Oncology Research and Education, Inc.

Statement of Financial Position For the Year Ended June 30, 2022

Assets

Cash	\$ 1,240,315
Grants receivable	779,012
Property and equipment, net	4,834
Other assets	<u>49,370</u>
Total assets	<u>\$ 2,073,531</u>

Liabilities and Net Assets

Liabilities:

Accounts payable and accrued liabilities	<u>\$ 494,146</u>
Total liabilities	<u>494,146</u>

Net assets:

Without donor restrictions:	
Undesignated	1,035,028
Designated by the Board	<u>500,000</u>
	1,535,028

With donor restrictions:

Purpose restrictions	<u>44,357</u>
Total net assets	<u>1,579,385</u>
Total liabilities and net assets	<u>\$ 2,073,531</u>

Georgia Center for Oncology Research and Education, Inc.

Statement of Activities For the Year Ended June 30, 2022

	Without Donor Restrictions	With Donor Restrictions	Total
Revenues, support and gains:			
Government grants	\$ 2,664,944	\$ -	\$ 2,664,944
Contributions and grants	117,684	-	117,684
Other revenue	280,146	-	280,146
Interest	79	-	79
Total revenues, support and gains	3,062,853	-	3,062,853
Expenses:			
Program activities	2,511,790	-	2,511,790
Supporting activities:			
Management and general	221,052	-	221,052
Development	61,580	-	61,580
Total supporting activities	282,632	-	282,632
Total expenses	2,794,422	-	2,794,422
Changes in net assets	268,431	-	268,431
Net assets, beginning of year	1,266,597	44,357	1,310,954
Net assets, end of year	\$ 1,535,028	\$ 44,357	\$ 1,579,385

Georgia Center for Oncology Research and Education, Inc.

Statement of Functional Expenses For the Year Ended June 30, 2022

	Program Activities	Supporting Activities			Total Expenses by Nature
		Management and General	Development	Total	
Research contracts	\$ 1,116,594	\$ -	\$ -	\$ -	\$ 1,116,594
Compensation and benefits	856,556	59,335	-	59,335	915,891
Fees for services	319,239	49,693	59,228	108,921	428,160
Advertising and promotion	76,388	2,545	225	2,770	79,158
Office expense	6,557	17,523	-	17,523	24,080
Information technology	28,834	33,954	-	33,954	62,788
Occupancy	41,266	10,316	-	10,316	51,582
Travel	11,854	4,644	-	4,644	16,498
Insurance	4,500	9,337	-	9,337	13,837
Telecommunications	2,673	15,573	-	15,573	18,246
Bank charges	19	1,197	-	1,197	1,216
Training	10,501	-	539	539	11,040
Other expenses	-	5,144	1,588	6,732	6,732
Depreciation and amortization	36,809	11,791	-	11,791	48,600
Total expenses by function	\$ 2,511,790	\$ 221,052	\$ 61,580	\$ 282,632	\$ 2,794,422

Georgia Center for Oncology Research and Education, Inc.

Statement of Cash Flows For the Year Ended June 30, 2022

Cash flows from operating activities

Cash provided by operating activities:

Cash received from donors and grantors	\$ 2,222,610
Cash received from clinical trials	68,222
Cash received from other sources	280,146
Cash received from interest	79

Cash used by operating activities:

Cash paid to employees	(915,891)
Cash paid to service providers and vendors	<u>(1,761,222)</u>

Net cash used by operating activities	<u>(106,056)</u>
---------------------------------------	------------------

Cash flows from investing activities

Cash purchases of property and equipment	<u>(12,474)</u>
--	-----------------

Net cash used by investing activities	<u>(12,474)</u>
---------------------------------------	-----------------

Net decrease in cash	(118,530)
----------------------	-----------

Cash, beginning of year	<u>1,121,785</u>
-------------------------	------------------

Cash, end of year	<u>\$ 1,240,315</u>
-------------------	---------------------

Supplemental disclosure of noncash activities:

Depreciation and amortization	\$ 49,984
-------------------------------	-----------

Georgia Center for Oncology Research and Education, Inc.

Notes to Financial Statements For the Year Ended June 30, 2022

1. NATURE OF ACTIVITIES

Georgia Center for Oncology Research and Education, Inc. (Georgia CORE or the Organization) was incorporated on March 26, 2003, under the laws of the state of Georgia as a not-for-profit corporation for the purpose of contributing to the state's distinction as a national leader in cancer care through a statewide network of care providers, scientists, and educators dedicated to providing resources for cancer prevention, treatment, research, and education. The Organization's primary funding is provided from grants and contributions and its corporate office is located in Atlanta, Georgia.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following significant accounting policies are described to enhance the usefulness of the financial statements to the reader.

Basis of Accounting

The Organization prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The Financial Accounting Standards Board (FASB) provides authoritative guidance regarding U.S. GAAP through the Accounting Standards Codification (ASC) and related Accounting Standards Updates (ASUs).

Reporting Period

The Organization has selected June 30 as its fiscal year end. Accordingly, the fiscal year ended June 30, 2022.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash

Cash and cash equivalents include cash, checking and savings accounts, and highly liquid investments that are readily convertible into cash and have a maturity of ninety days or less when purchased. At times, cash and cash equivalent balances may exceed federally insured amounts. The Organization has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

Grant Receivable

Grant receivables are unsecured, noninterest-bearing outstanding balances due from grantors less an allowance for uncollectible grants receivable based on an assessment of grant agreements and knowledge of circumstances that may affect the ability of the grantors to meet their obligations. Grant receivables are evaluated for impairment if full payments are not received in accordance with contractual terms. Grant receivables are written off when deemed uncollectible. At June 30, 2022, management has determined that no allowance for uncollectible grants receivable are required.

Property and Equipment

The Organization's capitalization policy is to capitalize property and equipment with a purchase price, or donation value, in excess of \$5,000 and which has a useful life greater than one year. Property and equipment purchased are recorded at cost, or fair value at the date of donation, if donated.

Maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed currently. Property items retired, or otherwise disposed of, are removed from the asset and accumulated depreciation accounts and any resulting gain or loss is reflected in the statement of activities.

Depreciation is provided over the estimated useful lives of the individual assets using the straight-line method as follows: furniture and computer equipment, 3 -7 years.

Leasehold improvements are amortized using the straight-line method over the lesser of the useful lives of the improvements or the term of the lease.

The Organization also amortizes website development costs over a two-year period.

Impairment

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. If a long-lived asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying value of the asset exceeds the fair value of the asset. There were no indicators of asset impairment for the year ended June 30, 2022.

Net Assets

To ensure observance of limitations and restrictions placed on the use of resources available to the Organization, amounts reported in the financial statements are classified in two self-balancing net asset categories as follows:

- Net assets without donor restrictions are resources currently available for use in general operations, including internal limits imposed by board decisions.
- Net assets with donor restrictions are resources whose use is limited by donor / grantor-imposed restrictions for specific purpose, passage of time, or perpetual donor-imposed stipulations that neither expire by the passage of time nor can be removed by actions of the Organization.

Recognition of Revenue

Unconditional Contributions

Contributions are reported when made, which is generally when cash (or notification of a beneficial interest) is received, unconditional promises to give are made, or ownership of donated assets is transferred to the Organization.

The Organization recognizes contributions as restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor-imposed temporary restriction expires, temporarily restricted net assets are reclassified to unrestricted net assets and presented in the accompanying statement of activities as net assets released from restrictions.

In certain cases, contributions are solicited for support and project accounts that have been previously funded by unrestricted resources in anticipation of receiving donor restricted contributions. Such contributions are immediately recognized as reclassifications to unrestricted support in the period received since the donor-imposed restrictions have already been satisfied.

Contributions to Acquire Long-Term Assets

Contributions of cash and other assets that must be used to acquire long-term assets are recognized as restricted support. In the absence of explicit donor stipulations about how long those long-term assets must be maintained, the Organization reports expirations of donor-imposed restrictions when the acquired long-term assets are placed into service.

Conditional Contributions

Conditional contributions received are either accounted for as a liability or are unrecognized initially until the barriers to entitlement are overcome, at which point the transaction is recognized as unconditional. There were no conditional contributions for the year ended June 30, 2022.

Exchange Transactions

The Organization receives revenue from grantors pursuant to grant contracts. The characteristics of each individual grant are considered to determine if a resource provider is receiving commensurate value in return for the resources transferred. A benefit received by the public is treated as a contribution and a benefit received by the resource provider is treated as an exchange transaction. Exchange transaction revenue is recorded as the costs are incurred for cost reimbursement grants or as the services are performed for operating and performance grants. Management has determined that all grants should be treated as contributions.

Donated Goods and Services

Unconditional contributions of goods are recorded at fair value at the date of donation. Conditional contributions of goods are either accounted for as a liability or are unrecognized initially until the barriers to entitlement are overcome, at which point the asset is recognized as unconditional. There were no conditional contributions of goods for the year ended June 30, 2022.

Contributions of long-term assets, such as property and equipment, are recorded as unrestricted support unless explicit donor stipulations specify how the long-term asset must be used. Contributions of long-term assets with explicit restrictions that specify how the assets are to be used are recognized as restricted support when received and are released from restrictions when the donated assets are placed into service.

Donated professional services that create or enhance nonfinancial assets, or require skills that would otherwise typically be purchased, are recorded as contributions at their estimated fair values when the services are rendered.

Major Collaboration Partners

During 2022, the Organization had four major grantors accounting for approximately 88.34% of total contributions and grants.

Advertising Costs

Advertising costs, which are reflected as advertising and promotion, consist primarily of direct advertisements, graphic design, promotional materials, and participation in health fairs, are expensed as incurred. During 2022, advertising costs totaled \$79,158.

Allocation of Expenses

The costs of providing the various programs and other activities have been summarized in the accompanying financial statements. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Except for depreciation and occupancy, all expenses are allocated based on an estimate of where time and efforts are made, and benefits are received. Depreciation and occupancy are allocated based on estimated usage and square footage.

Tax-Exempt Status

The Organization has been organized as a Georgia not-for-profit corporation, recognized by the IRS as exempt from federal income tax under Internal Revenue Code Section 501(c)(3), and determined not to be a private foundation.

The Organization is annually required to file a Return of Organization Exempt from Income Tax (Form 990) with the IRS. In addition, the Organization is subject to income tax on net income derived from business activities that are unrelated to its exempt purpose. Management has determined that the Organization had no unrelated business income during the year of 2022 and has not filed an Exempt Organization Business Income Tax Return (Form 990-T) with the IRS.

The Organization only recognizes the tax benefit from an uncertain tax position taken or to be taken in a tax return if the tax position is more likely than not to be sustained upon an examination, based on the technical merits of the position. Management has analyzed tax positions taken for filings with the IRS and all state jurisdictions where the Organization operates. Management believes that income tax filing positions would be sustained upon examination and does not anticipate that any adjustments would result in a material adverse effect on the Organization's financial condition, results of operations or cash flows. Accordingly, the Organization has not recorded any reserves, or related accruals for interest and penalties for uncertain income tax positions for the year ended June 30, 2022.

The Organization is subject to federal and state examinations, generally three years from the date that the returns are filed; currently there are no examinations in progress for any tax periods. The Organization believes it is no longer subject to income tax examinations for fiscal years prior to 2019.

Credit Risk and Geographic Concentration

For the year ended June 30, 2022, three collaboration partners accounted for 92.75% of the outstanding grants receivable balance. Credit risk associated with grants receivable is considered to be limited due to high historical collection rates and because outstanding amounts are due from collaboration partners supportive of the Organization's mission.

The Organization conducts its operations solely within the state of Georgia, and, therefore, is subject to risks from changes in political and local economic conditions. A change in politics or a downturn in the local economy could cause a decrease in contributions and grants concurrently with an increase in community need for the Organization's services.

3. PROPERTY AND EQUIPMENT

A summary of property and equipment at June 30, 2022 follows:

Computer equipment	\$	30,556
Furniture		23,901
		54,457
Less accumulated depreciation		(49,623)
Net property and equipment	\$	4,834

Depreciation expense for 2022 was \$3,866.

4. OTHER ASSETS

A summary of other assets at June 30, 2022 is as follows:

Prepays	\$	24,541
Security deposit		3,096
Website development		184,612
		212,249
Less website amortization		(162,879)
Total other assets	\$	49,370

Amortization expense related to the website totaled \$42,781 for 2022.

5. COMMITMENTS

Operating Leases

In September 2020, the Organization entered into a new operating lease for the use of the building for operations that will expire in fiscal year 2023 with an option to renew indefinitely. The lease requires monthly lease payments of \$4,075 for 2022. The remaining lease payments to be paid during the year ended June 30, 2023 total \$24,448.

Rent expense for the year of June 30, 2022, which includes payments for base rent additional ancillary fees such as insurance, utilities, and property taxes, totaled \$51,582 for facility rental and is included in occupancy expense.

In January, 2020, the Organization entered into a lease agreement for office equipment that has been accounted for as a capital lease. The office equipment has been capitalized at the lesser of fair market value or the present value of the minimum lease payments at the inception of the lease using the Organization's incremental borrowing rate.

The future minimum payments under the capital lease, together with the present value of the minimum lease payments total \$1,114 for 2023.

Grant Compliance

Certain grants entered into by the Organization are subject to discretionary review by the grantor agencies, which could result in requests for reimbursements of disallowed costs or noncompliance with grantor restrictions. Currently there are no grantor agency reviews in progress and management believes that the Organization has adhered to the terms of its grants and such reviews, if they occur, are not expected to have a material adverse effect on the Organization's past results. Should the amount of these grants decrease, the Organization may be adversely affected.

6. NET ASSETS WITHOUT DONOR RESTRICTIONS

A summary of net assets without donor restrictions at June 30, 2022 were as follows:

Undesignated	\$ 1,035,028
Designated by the Board	
Board designated for sustainability	300,000
Board designated for strategic initiatives	200,000
Total net assets without donor restrictions	\$ 1,535,028

7. NET ASSETS WITH DONOR RESTRICTIONS

A summary of net assets with donor restrictions at June 30, 2022 were as follows:

Subject to expenditure for specific purpose:	
Genetic testing	\$ 44,357
Total net assets with donor restrictions	\$ 44,357

8. LIQUIDITY AND AVAILABILITY DISCLOSURES

The Organization prepares an annual budget that is reviewed and approved by the Board of Directors in advance of the upcoming year. Periodic meetings are held by the Finance Committee to review internal financial statements and budget to actual comparisons. The Organization does not commit to expenditures if cash is not available to pay the expenditures immediately.

Following is a schedule reflecting the financial assets available to meet cash needs for general expenditures within one year:

Financial assets, at year end:	
Cash	\$ 1,240,315
Grants receivable expected to be collected within one year	779,012
	<u>2,019,327</u>
Less:	
Donor-imposed restrictions likely to be met by expenditure within one year making financial assets unavailable for general expenditure	(44,357)
Liabilities to be paid within one year	(494,146)
Board designated liquidity reserve	<u>(500,000)</u>
Financial assets available to meet cash needs for general expenditures within one year	<u>\$ 980,824</u>

9. RELATED PARTIES

A summary of related parties for the year ended June 30, 2022 follows:

Nature of service:	
Contributions from board members, employees, and affiliates	\$ 14,150

10. SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date of the auditor's report, the date on which the financial statements were available to be issued. Subsequent events after that date have not been evaluated. In general, these events are recognized in the financial statements if the conditions existed at the date of the statement of financial position, but are not recognized if the conditions did not exist at the statement of the financial position date. The Organization discloses non-recognized events it required to keep the financial statements from being misleading. There were no events identified by Management that require disclosure.

REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM AND REPORT ON INTERNAL CONTROL OVER COMPLIANCE IN ACCORDANCE WITH THE UNIFORM GUIDANCE

To the Board of Directors and Management of
Georgia Center for Oncology Research and Education, Inc.
Buford, Georgia

Opinion on Each Major Federal Program

We have audited the Georgia Center for Oncology Research and Education, Inc. (the Organization), compliance with the types of compliance requirements described in the OMB Compliance Supplement, that could have a direct and material effect on each of the Organization's major federal programs for the year ended June 30, 2022. The Organization's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Organization complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in Government Auditing Standards (GAS), issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and the State Single Audit Implementation Act. Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provides a reasonable basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Organization's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Organization's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Organization's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with Government Auditing Standards (GAS), and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Organization's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAS, and the Uniform Guidance, we

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Organization's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Organization's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in Auditor's Responsibilities for the Audit of Compliance section and above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies or material weaknesses in internal control over compliance. Given these limitations, during our audit, we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified. Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



K. Glenn Aldridge, PC
(d/b/a Aldridge & Associates)
February 27, 2023

Georgia Center for Oncology Research and Education, Inc.
Schedule Of Findings And Questioned Costs
For The Year Ended June 30, 2022

Section I - Summary of Auditor's Results

Financial Statements

Type of auditor's report issued:	Unmodified
Internal control over financial reporting:	
Material weakness identified?	None
Significant deficiency identified?	None
Noncompliance material to financial statements noted?	No.

Federal Awards

Internal control over major federal programs:	
Material weakness identified?	No.
Significant deficiency identified?	No.
Type of auditor's report issued on compliance for major federal programs:	Unmodified.
Any audit findings disclosed that are required to be reported in accordance with 2 §CFR 910.516(a)?	No.

Identification of major federal program:

<u>CFDA #</u>	<u>Award Name / Number</u>	<u>Type of Report Issued</u>
93.800	Organized Approaches to Increase Colorectal Cancer Screening	Unmodified.
93.399	Cancer Control	Unmodified.

Dollar threshold used to distinguish between type A and type B programs:	\$750,000
Auditee qualified as low-risk auditee?	No.

Section II - Financial Statement Findings

None

Section III - Federal Award Findings and Questioned Costs

None

Georgia Center for Oncology Research and Education, Inc.
Schedule of Expenditures of Federal Awards
June 30, 2022

Federal Grantor/Pass-Through Grantor/Program	Federal CFDA Number	Expenditures
U.S. Department of Health and Human Services:		
Pass-through program from:		
<i>Center of Disease Control and Prevention</i>		
Organized Approaches to Increase Colorectal Cancer Screening	93.800	984,379
<i>National Institutes of Health</i>		
Cancer Control	93.399	474,498
Total U.S. Department of Health and Human Services		1,458,877
Total Expenditures of Federal Awards		\$ 1,458,877

Notes to Schedule of Expenditures of Federal Awards

(1) BASIS OF PRESENTATION

This Schedule is prepared in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Parts 200 and 910, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the Organization, it is not intended to and does not present the financial position, changes in financial position, or cash flows of the Organization.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Expenditures reported in this Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in *Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, wherein certain types of expenditures are not allowable or are limited to reimbursement.

(3) CONTINGENCIES

Grant monies received and disbursed are for specific purposes and are subject to review by the grantor agencies. Such audits result in requests for reimbursement due to disallowed expenditures. Management does not believe that such disallowance, if any, would have a material effect on its financial position. As of June 30, 2022 there were no material questioned or disallowed costs as a result of the grant audits in process or completed.

(4) INDIRECT COST

The Organization have elected to use the 10% de minimis indirect cost rate.

**Georgia Center for Oncology Research and Education, Inc.
Summary of Schedule of Prior Year Findings and Questioned Costs
For The Year Ended June 30, 2021.**

There were no prior year findings.
